<code id='8E38447729'></code><style id='8E38447729'></style>
    • <acronym id='8E38447729'></acronym>
      <center id='8E38447729'><center id='8E38447729'><tfoot id='8E38447729'></tfoot></center><abbr id='8E38447729'><dir id='8E38447729'><tfoot id='8E38447729'></tfoot><noframes id='8E38447729'>

    • <optgroup id='8E38447729'><strike id='8E38447729'><sup id='8E38447729'></sup></strike><code id='8E38447729'></code></optgroup>
        1. <b id='8E38447729'><label id='8E38447729'><select id='8E38447729'><dt id='8E38447729'><span id='8E38447729'></span></dt></select></label></b><u id='8E38447729'></u>
          <i id='8E38447729'><strike id='8E38447729'><tt id='8E38447729'><pre id='8E38447729'></pre></tt></strike></i>

          Home / Wikipedia / Wikipedia

          Wikipedia


          Wikipedia

          author:Wikipedia    Page View:2
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In